Welcome to LookChem.com Sign In|Join Free

CAS

  • or

177911-87-4

Post Buying Request

177911-87-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

177911-87-4 Usage

General Description

2-(Aminomethyl)-1-N-Boc-pyrrolidine is a chemical compound with the formula C10H19NO2. It is classified as an amine and contains a pyrrolidine ring. The N-Boc group in the name refers to the tert-butoxycarbonyl protecting group, which is often used in organic synthesis to protect amines and other functional groups. 2-(Aminomethyl)-1-N-Boc-pyrrolidine is commonly used in the synthesis of pharmaceuticals and other organic compounds due to its versatile reactivity and ability to form various chemical bonds. It is an important intermediate in the production of many bioactive molecules and is commonly used in the pharmaceutical industry.

Check Digit Verification of cas no

The CAS Registry Mumber 177911-87-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,9,1 and 1 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 177911-87:
(8*1)+(7*7)+(6*7)+(5*9)+(4*1)+(3*1)+(2*8)+(1*7)=174
174 % 10 = 4
So 177911-87-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H20N2O2/c1-10(2,3)14-9(13)12-6-4-5-8(12)7-11/h8H,4-7,11H2,1-3H3/p+1/t8-/m1/s1

177911-87-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H28650)  (±)-1-Boc-2-(aminomethyl)pyrrolidine, tech. 85%   

  • 177911-87-4

  • 250mg

  • 372.0CNY

  • Detail
  • Alfa Aesar

  • (H28650)  (±)-1-Boc-2-(aminomethyl)pyrrolidine, tech. 85%   

  • 177911-87-4

  • 1g

  • 955.0CNY

  • Detail
  • Alfa Aesar

  • (H28650)  (±)-1-Boc-2-(aminomethyl)pyrrolidine, tech. 85%   

  • 177911-87-4

  • 5g

  • 2960.0CNY

  • Detail
  • Aldrich

  • (721824)  1-Boc-2-(aminomethyl)pyrrolidine  

  • 177911-87-4

  • 721824-1G

  • 939.51CNY

  • Detail

177911-87-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate

1.2 Other means of identification

Product number -
Other names tert-Butyl 2-(aminomethyl)pyrrolidine-1-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:177911-87-4 SDS

177911-87-4Downstream Products

177911-87-4Relevant articles and documents

Discovery of Arylsulfonamide Nav1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile

Ballard, Jeanine E.,Brunskill, Andrew P. J.,Burgey, Christopher S.,Clements, Michelle,Daley, Christopher,Greshock, Thomas J.,Houghton, Andrea K.,Jovanovska, Aneta,Kelly, Michael J.,Klein, Rebecca,Kraus, Richard L.,Layton, Mark E.,Li, Yuxing,Peng, Xuanjia,Pero, Joseph E.,Roecker, Anthony J.,Sun, Haiyan,Wang, Deping,Wang, Xiu,Zhao, Fuqiang

supporting information, p. 1038 - 1049 (2021/06/28)

The voltage-gated sodium channel Nav1.7 continues to be a high-profile target for the treatment of various pain afflictions due to its strong human genetic validation. While isoform selective molecules have been discovered and advanced into the clinic, to date, this target has yet to bear fruit in the form of marketed therapeutics for the treatment of pain. Lead optimization efforts over the past decade have focused on selectivity over Nav1.5 due to its link to cardiac side effects as well as the translation of preclinical efficacy to man. Inhibition of Nav1.6 was recently reported to yield potential respiratory side effects preclinically, and this finding necessitated a modified target selectivity profile. Herein, we report the continued optimization of a novel series of arylsulfonamide Nav1.7 inhibitors to afford improved selectivity over Nav1.6 while maintaining rodent oral bioavailability through the use of a novel multiparameter optimization (MPO) paradigm. We also report in vitro-in vivo correlations from Nav1.7 electrophysiology protocols to preclinical models of efficacy to assist in projecting clinical doses. These efforts produced inhibitors such as compound 19 with potency against Nav1.7, selectivity over Nav1.5 and Nav1.6, and efficacy in behavioral models of pain in rodents as well as inhibition of rhesus olfactory response indicative of target modulation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 177911-87-4